Recent from talks
Philidor Rx Services
Knowledge base stats:
Talk channels stats:
Members stats:
Philidor Rx Services
Philidor Rx Services is a Pennsylvania-licensed specialty online pharmacy, which mainly sold Valeant Pharmaceuticals International Inc drugs directly to patients and handled insurance claims on the customers' behalf.
BQ6 Media Group LLC is a "privately held marketing firm specializing in pharmaceutical marketing, communications and promotion" based in Philadelphia, PA, with its headquarter in Horsham, PA, a group that did consulting work for Valeant, among other pharmaceutical companies. BQ6 Media, which is located just four kilometres from Philidor's head office, self-defined as game theorists that combined "creative vision with empirical data and market expertise." On their webpage they offer to help clients in the pharmaceutical industry "ensure your brand is moves ahead" using zero-sum game theory concepts. They develop "innovative strategies" to move pharmaceutical products from "pipeline to endgame." Philidor is part of a network of companies, including BQ6 Media Group LLC and Isolani LLC. Philidor RX Services created Isolani LLC. The name Philidor refers to an 18th-century French Chess master Francois-Andre Philidor and the Philidor position, an important chess Chess endgame; isolani refers to an isolated pawn. BQ6 Media is named after the chess shorthand for Bobby Fischer's legendary move against Russian chess master Boris Spassky in 1972. The Southern Investigative Reporting Foundation (SIRF) report alleges that several states list Matthew Davenport, David Wing, John Carne and Gregory Blaszcynski as officers of BQ6 Media and another company, End Game Partnership LLP (chess reference), as assistant treasurer. The SIRF report pointed to another reference to a popular chess move called the King's Gambit Accepted (KGA) that is also the name of Valeant's wholly owned unit — KGA Fulfillment Services Inc., formed in Delaware in November 2014.
Philidor Rx Services was formed in 2013 by Matthew S. Davenport and Andrew (Andy) Davenport as an online pharmacy in Delaware with an office in Horsham, Pennsylvania and in Hatboro, a town of about 7,360 in Montgomery County, Pennsylvania.
California is the "largest market for medicines" in the US and Philidor and Valeant faced "hurdles in getting prescriptions filled there. In August 2013 Philidor had requested an application for a California Non-Residency Pharmacy Permit but it was denied in May 2014 by State Attorney General Kamala Harris's staff because Philidor allegedly falsified information on its application, claiming that Matthew Davenport was registered as Philidor's principal when Andrew (Andrew) Davenport was the principal and did not disclose that Andrew owned 27% of Philidor. There were other "false statement of facts" on the application and Philidor was accused of unprofessional conduct.
On December 1, 2014, 64-year-old pharmacist Russell Reitz sold his small three-year-old specialty pharmacy prescription-filling mail-order business — R&O Pharmacy — in Camarillo, in suburban Los Angeles for $350,000 to Isolani LLC. Reitz stayed on as manager. Prior to the acquisition by Isolani, R&O Pharmacy had dispensed a modest number of prescription medications to patients and collected reimbursements from insurance companies. With the new owners, Isolani and Philidor, Reitz' store's name R&O Pharmacy, and his National Council for Prescription Drug Programs identification number were used to fill prescriptions nationwide at other pharmacies which amounted to $230 million a year. Reitz became concerned and in July he sent emails to Andy Davenport CEO of Philidor and Eric Rice of Isolani. In the emails Reitz, claimed that his personal "ID was used to bill for prescriptions" that were "filled by some other pharmacy (in some cases for drugs that R&O did not even stock)" or "filled and billed" before the R&O purchase agreement was finalized.
Another pharmacy in the Philidor network is West Wilshire Pharmacy in Los Angeles.
According to a Wall Street Journal article in October 2015, "Valeant employees were placed at Philidor while the pharmacy was in its infancy" to provide help on "structures and processes." In 2014, Philidor created 250 new jobs. In an October 26, 2015 conference call Valeant CEO J. Michael Pearson said, Valeant had paid $100 million in late 2014 for an option to buy Philidor for nothing over the next 10 years. In turn Philidor "has an option to buy a Delaware entity called Isolani LLC, which has an agreement to buy" Camarillo, California-based specialty pharmacy R&O Pharmacy.
Most of the prescriptions filled by Philidor were for Valeant's expensive drugs like Solodyn, an oral antibiotic approved to treat moderate to severe acne and Jublia, a treatment for onychomycosis of the toenails. They also filled Retin-A Micro (tretinoin) prescriptions. Jublia, which received FDA approval in July 2014 and a new 0.08% formulation of Retin-A Micro, which received FDA approval in January 2014, were two products among others that Valeant acquired with the purchase of Dow Pharmaceuticals in 2008.
Hub AI
Philidor Rx Services AI simulator
(@Philidor Rx Services_simulator)
Philidor Rx Services
Philidor Rx Services is a Pennsylvania-licensed specialty online pharmacy, which mainly sold Valeant Pharmaceuticals International Inc drugs directly to patients and handled insurance claims on the customers' behalf.
BQ6 Media Group LLC is a "privately held marketing firm specializing in pharmaceutical marketing, communications and promotion" based in Philadelphia, PA, with its headquarter in Horsham, PA, a group that did consulting work for Valeant, among other pharmaceutical companies. BQ6 Media, which is located just four kilometres from Philidor's head office, self-defined as game theorists that combined "creative vision with empirical data and market expertise." On their webpage they offer to help clients in the pharmaceutical industry "ensure your brand is moves ahead" using zero-sum game theory concepts. They develop "innovative strategies" to move pharmaceutical products from "pipeline to endgame." Philidor is part of a network of companies, including BQ6 Media Group LLC and Isolani LLC. Philidor RX Services created Isolani LLC. The name Philidor refers to an 18th-century French Chess master Francois-Andre Philidor and the Philidor position, an important chess Chess endgame; isolani refers to an isolated pawn. BQ6 Media is named after the chess shorthand for Bobby Fischer's legendary move against Russian chess master Boris Spassky in 1972. The Southern Investigative Reporting Foundation (SIRF) report alleges that several states list Matthew Davenport, David Wing, John Carne and Gregory Blaszcynski as officers of BQ6 Media and another company, End Game Partnership LLP (chess reference), as assistant treasurer. The SIRF report pointed to another reference to a popular chess move called the King's Gambit Accepted (KGA) that is also the name of Valeant's wholly owned unit — KGA Fulfillment Services Inc., formed in Delaware in November 2014.
Philidor Rx Services was formed in 2013 by Matthew S. Davenport and Andrew (Andy) Davenport as an online pharmacy in Delaware with an office in Horsham, Pennsylvania and in Hatboro, a town of about 7,360 in Montgomery County, Pennsylvania.
California is the "largest market for medicines" in the US and Philidor and Valeant faced "hurdles in getting prescriptions filled there. In August 2013 Philidor had requested an application for a California Non-Residency Pharmacy Permit but it was denied in May 2014 by State Attorney General Kamala Harris's staff because Philidor allegedly falsified information on its application, claiming that Matthew Davenport was registered as Philidor's principal when Andrew (Andrew) Davenport was the principal and did not disclose that Andrew owned 27% of Philidor. There were other "false statement of facts" on the application and Philidor was accused of unprofessional conduct.
On December 1, 2014, 64-year-old pharmacist Russell Reitz sold his small three-year-old specialty pharmacy prescription-filling mail-order business — R&O Pharmacy — in Camarillo, in suburban Los Angeles for $350,000 to Isolani LLC. Reitz stayed on as manager. Prior to the acquisition by Isolani, R&O Pharmacy had dispensed a modest number of prescription medications to patients and collected reimbursements from insurance companies. With the new owners, Isolani and Philidor, Reitz' store's name R&O Pharmacy, and his National Council for Prescription Drug Programs identification number were used to fill prescriptions nationwide at other pharmacies which amounted to $230 million a year. Reitz became concerned and in July he sent emails to Andy Davenport CEO of Philidor and Eric Rice of Isolani. In the emails Reitz, claimed that his personal "ID was used to bill for prescriptions" that were "filled by some other pharmacy (in some cases for drugs that R&O did not even stock)" or "filled and billed" before the R&O purchase agreement was finalized.
Another pharmacy in the Philidor network is West Wilshire Pharmacy in Los Angeles.
According to a Wall Street Journal article in October 2015, "Valeant employees were placed at Philidor while the pharmacy was in its infancy" to provide help on "structures and processes." In 2014, Philidor created 250 new jobs. In an October 26, 2015 conference call Valeant CEO J. Michael Pearson said, Valeant had paid $100 million in late 2014 for an option to buy Philidor for nothing over the next 10 years. In turn Philidor "has an option to buy a Delaware entity called Isolani LLC, which has an agreement to buy" Camarillo, California-based specialty pharmacy R&O Pharmacy.
Most of the prescriptions filled by Philidor were for Valeant's expensive drugs like Solodyn, an oral antibiotic approved to treat moderate to severe acne and Jublia, a treatment for onychomycosis of the toenails. They also filled Retin-A Micro (tretinoin) prescriptions. Jublia, which received FDA approval in July 2014 and a new 0.08% formulation of Retin-A Micro, which received FDA approval in January 2014, were two products among others that Valeant acquired with the purchase of Dow Pharmaceuticals in 2008.